To make full use of the advantages provided by amorphous pharmaceuticals it is necessary to understand the basic factors that determine their physical and chemical stability. Molecular mobility seems to be the most important one. Unfortunately, due to the exceedingly long time scale required for molecular motion in the glassy state, direct monitoring of the structural α-relaxation time () in this temperature regime is rather difficult. A thorough investigation was carried out of the time scale of α-mobility in the glassy state of telmisartan (TEL). For this drug, global molecular mobility seems to be the most dominant factor responsible for its long-term stability. Based on some estimations obtained previously it was concluded that at room temperature, molecular mobility associated with the structural relaxation would exceed three years. To characterize the temperature behavior of structural relaxation below the glass transition temperature, T g, a modified Adam–Gibbs approach was used. Additionally, using results of dielectric measurements, a comparative analysis was performed of the molecular dynamics of amorphous TEL prepared by cryomilling as well as obtained by quench-cooling of the melt. An X-ray diffraction analysis was also carried out to confirm the long-term stability of amorphous TEL, whereas solubility studies revealed its markedly better solubility profile than that for the crystalline form. These findings have important implications for further handling of this drug.
No takes yet. Share an insight, caveat, or question.
Adrjanowicz et al. (2011) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: